BJH - volume 14, issue 1, february 2023
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this overview, we present what was new in the field of haematopoietic cell transplantation (HCT) at ASH 2022. Key messages were that all AML patients – even those without complete remission – are eligible for HCT and that there is a donor for (virtually) everybody thanks to the use of post-transplant cytarabine and abatercept. Furthermore, first-line acute graft-versus-host disease treatment in standard risk patients is feasible without corticosteroids or with low-dose corticosteroids. Finally, it was reported that a non-restrictive diet does not increase infections in patients with neutropenia after stem cell transplantation.
(BELG J HEMATOL 2023;14(1):26–9)
Read moreBJH - volume 13, issue 7, november 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.
(BELG J HEMATOL 2022;13(7):285–8)
Read moreBJH - volume 13, issue 6, october 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.
(BELG J HEMATOL 2022;13(6):256–9)
Read moreBJH - volume 13, issue 5, september 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
During the past European Hematology Association’s annual congress (EHA 2022), four oral sessions were devoted to clinical trials and recent advances in myeloma. These sessions covered newly diagnosed multiple myeloma (MM), antibody-based therapy in relapsed/refractory (RR) MM, BCMA-directed treatment in RRMM and biology and translational research. Below, we summarise the highlights from some of the studies that were presented in each of these sessions.
(BELG J HEMATOL 2022;13(5):219–23)
Read moreBJH - volume 13, issue 4, june 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (
(BELG J HEMATOL 2022;13(4):175–8)
Read moreBJH - volume 13, issue 3, may 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.
(BELG J HEMATOL 2022;13(3):137–40)
Read moreBJH - volume 13, issue 2, march 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this section of the BJH, we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.
(BELG J HEMATOL 2022;13(2):101–3)
Read more
Top
